- Home
- MTR vs ENSC Comparison
MTR vs ENSC Comparison
Compare MTR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- ENSC
- Stock Information
- Founded
- MTR 1979
- ENSC 2003
- Country
- MTR United States
- ENSC United States
- Employees
- MTR N/A
- ENSC N/A
- Industry
- MTR Oil & Gas Production
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- ENSC Health Care
- Exchange
- MTR Nasdaq
- ENSC Nasdaq
- Market Cap
- MTR 11.8M
- ENSC 9.5M
- IPO Year
- MTR N/A
- ENSC N/A
- Fundamental
- Price
- MTR $6.33
- ENSC $6.07
- Analyst Decision
- MTR
- ENSC
- Analyst Count
- MTR 0
- ENSC 0
- Target Price
- MTR N/A
- ENSC N/A
- AVG Volume (30 Days)
- MTR 14.1K
- ENSC 154.9K
- Earning Date
- MTR 01-01-0001
- ENSC 11-12-2024
- Dividend Yield
- MTR 3.56%
- ENSC N/A
- EPS Growth
- MTR N/A
- ENSC N/A
- EPS
- MTR 0.35
- ENSC N/A
- Revenue
- MTR $966,169.00
- ENSC $4,421,404.00
- Revenue This Year
- MTR N/A
- ENSC N/A
- Revenue Next Year
- MTR N/A
- ENSC N/A
- P/E Ratio
- MTR $18.20
- ENSC N/A
- Revenue Growth
- MTR N/A
- ENSC 40.41
- 52 Week Low
- MTR $5.60
- ENSC $2.12
- 52 Week High
- MTR $14.49
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- MTR 43.26
- ENSC 42.77
- Support Level
- MTR $6.06
- ENSC $5.34
- Resistance Level
- MTR $6.79
- ENSC $8.27
- Average True Range (ATR)
- MTR 0.31
- ENSC 1.06
- MACD
- MTR -0.10
- ENSC -0.24
- Stochastic Oscillator
- MTR 20.77
- ENSC 18.43
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.